Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14532720 | 0.84 | ALDH1A1 (0.32) | ALDH1A1ATMMAPTNPSR1 | |
| SCHEMBL16205774 | 0.81 | ACHE (0.32) | ALDH1A1ATMMAPTNPSR1CTSK | |
| SCHEMBL13519736 | 0.80 | AAK1 (0.42) | ALDH1A1ATMMAPTNPSR1HPGD | |
| SCHEMBL16205781 | 0.79 | PDK2 (0.32) | ALDH1A1MAPT | |
| SCHEMBL7020025 | 0.78 | CA12 (0.38) | SMN1; SMN2 | |
| SCHEMBL13682813 | 0.78 | CA12 (0.38) | SMN1; SMN2 | |
| SCHEMBL5058562 | 0.77 | ALDH1A1 (0.35) | ALDH1A1ATMMAPTNPSR1HPGD | |
| SCHEMBL23542745 | 0.76 | AAK1 (0.30) | — | |
| SCHEMBL17293178 | 0.76 | FAAH (0.36) | ALDH1A1ATMMAPTHPGDCTSK | |
| SCHEMBL26449216 | 0.76 | NFKB1 (0.35) | HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2989088-B1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PF MEDICAMENT (FR) | 2017-09-27 | — | — | EP | disclosed |
| US-9669106-B2 | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2017-06-06 | — | — | US | disclosed |
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-04-27 | — | — | US | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| WO-2016173682-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2016-11-03 | — | — | WO | disclosed |
| US-20160083420-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-24 | — | — | US | disclosed |
| US-20160068567-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| WO-2015162291-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162293-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| WO-2014174064-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014174062-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014174060-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | ALDH1A1 982/4885ATM 2759/4885MAPT 1611/4885 |
| US-20160083420-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, AURKC, DHCR7 | ALDH1A1 2654/4885ATM 2955/4885MAPT 3407/4885 |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | AURKC, AURKA, EGFR | ALDH1A1 1383/4885ATM 888/4885MAPT 1882/4885 |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | ALDH1A1 2976/4885ATM 3268/4885MAPT 3803/4885 |
| US-20160068567-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | CDK10, AURKC, AURKA | ALDH1A1 2793/4885ATM 2728/4885MAPT 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.